BR112022011892A2 - Composições farmacêuticas intranasais de inibidores de cgrp - Google Patents

Composições farmacêuticas intranasais de inibidores de cgrp

Info

Publication number
BR112022011892A2
BR112022011892A2 BR112022011892A BR112022011892A BR112022011892A2 BR 112022011892 A2 BR112022011892 A2 BR 112022011892A2 BR 112022011892 A BR112022011892 A BR 112022011892A BR 112022011892 A BR112022011892 A BR 112022011892A BR 112022011892 A2 BR112022011892 A2 BR 112022011892A2
Authority
BR
Brazil
Prior art keywords
cgrp
pharmaceutical compositions
intranasal pharmaceutical
inhibitors
intranasal
Prior art date
Application number
BR112022011892A
Other languages
English (en)
Inventor
Coric Vladimir
M Conway Charles
Croop Robert
Kumar Rajesh
Original Assignee
Biohaven Pharm Holding Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biohaven Pharm Holding Co Ltd filed Critical Biohaven Pharm Holding Co Ltd
Publication of BR112022011892A2 publication Critical patent/BR112022011892A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/006—Sprayers or atomisers specially adapted for therapeutic purposes operated by applying mechanical pressure to the liquid to be sprayed or atomised
    • A61M11/007—Syringe-type or piston-type sprayers or atomisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/04—Sprayers or atomisers specially adapted for therapeutic purposes operated by the vapour pressure of the liquid to be sprayed or atomised
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/08—Inhaling devices inserted into the nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/04—Liquids
    • A61M2202/0468—Liquids non-physiological

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Otolaryngology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mechanical Engineering (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

COMPOSIÇÕES FARMACÊUTICAS INTRANASAIS DE INIBIDORES DE CGRP. Trata-se de uma composição farmacêutica para distribuição intranasal, em que a composição farmacêutica inclui um ingrediente terapeuticamente ativo que inclui um inibidor de CGRP. Também é fornecido um método para distribuir um inibidor de CGRP a um sujeito, em que o método inclui a administração via intranasal ao sujeito de uma composição que inclui um componente terapeuticamente ativo que inclui um inibidor de CGRP.
BR112022011892A 2019-12-17 2020-12-17 Composições farmacêuticas intranasais de inibidores de cgrp BR112022011892A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962949351P 2019-12-17 2019-12-17
PCT/US2020/065452 WO2021127070A1 (en) 2019-12-17 2020-12-17 Intranasal pharmaceutical compositions of cgrp inhibitors

Publications (1)

Publication Number Publication Date
BR112022011892A2 true BR112022011892A2 (pt) 2022-09-06

Family

ID=76478147

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022011892A BR112022011892A2 (pt) 2019-12-17 2020-12-17 Composições farmacêuticas intranasais de inibidores de cgrp

Country Status (11)

Country Link
US (1) US20220401439A1 (pt)
EP (1) EP4076395A4 (pt)
JP (1) JP2023507094A (pt)
KR (1) KR20220114613A (pt)
CN (1) CN114980862A (pt)
AU (1) AU2020408705A1 (pt)
BR (1) BR112022011892A2 (pt)
CA (1) CA3164445A1 (pt)
IL (1) IL293647A (pt)
MX (1) MX2022007336A (pt)
WO (1) WO2021127070A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL302948A (en) * 2020-11-19 2023-07-01 Pfizer Ireland Pharmaceuticals Preparations for the administration of CGRP inhibitors
USD1001997S1 (en) * 2021-02-15 2023-10-17 Aptar Frances Sas Device for nasal spray
CN115429882A (zh) * 2022-10-19 2022-12-06 上海交通大学医学院附属第九人民医院 伤害性感觉神经细胞调控药物的用途
CN116003387B (zh) * 2022-11-20 2024-03-26 药康众拓(北京)医药科技有限公司 一种氘代吲唑丙酰胺类化合物、药物组合物和用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040076587A1 (en) * 2002-06-19 2004-04-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical composition for intranasal administration containing a CGRP antagonist
US8481546B2 (en) * 2010-03-30 2013-07-09 Bristol-Myers Squibb Company CGRP receptor antagonist
CA2922993A1 (en) * 2013-09-11 2015-03-19 Bixa Research And Health Inc. Single use intranasal atomizer
US20180185360A1 (en) * 2015-06-29 2018-07-05 Galderma Research & Development Cgrp receptor antagonist compounds for topical treatment of skin disorders
GB201519194D0 (en) * 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP receptor antagonists
US10913783B2 (en) * 2016-04-15 2021-02-09 H. Lundbeck A/S Humanized anti-PACAP antibodies and uses thereof
JP6885945B2 (ja) * 2016-07-22 2021-06-16 キッセイ薬品工業株式会社 ピロリジン誘導体
US20190135927A1 (en) * 2017-09-29 2019-05-09 Bhl Patent Holdings, Llc Migraine, headache, chronic pain treatment, and prophylaxis options
KR20200135465A (ko) * 2018-03-25 2020-12-02 바이오하벤 파마슈티컬 홀딩 컴퍼니 엘티디. Cgrp 관련 장애를 위한 리메게판트
CA3133912A1 (en) * 2019-04-18 2020-10-22 Allergan Sales, Llc Cgrp antagonists for the treatment of medication overuse headache, post-traumatic headache, post-concussion syndrome and vertigo

Also Published As

Publication number Publication date
US20220401439A1 (en) 2022-12-22
AU2020408705A1 (en) 2022-03-24
JP2023507094A (ja) 2023-02-21
WO2021127070A1 (en) 2021-06-24
MX2022007336A (es) 2022-09-19
EP4076395A1 (en) 2022-10-26
EP4076395A4 (en) 2024-02-07
CN114980862A (zh) 2022-08-30
KR20220114613A (ko) 2022-08-17
IL293647A (en) 2022-08-01
CA3164445A1 (en) 2021-06-24

Similar Documents

Publication Publication Date Title
BR112022011892A2 (pt) Composições farmacêuticas intranasais de inibidores de cgrp
MX2020007853A (es) Composiciones farmaceuticas para el tratamiento de fibrosis quistica.
NI201700100A (es) Composiciones farmacéuticas para terapia combinada
BR112017014067A2 (pt) composição para tratar doenças relacionadas a il-6
BR112018007947A2 (pt) uso de antagonistas de receptor ep4 para o tratamento de câncer de fígado associado a nash
BR112017016817A2 (pt) derivados heterocíclicos formilados como inibidores de fgfr4
BR112013021566A2 (pt) composto de fórmula, ou um aduto ou sal farmaceuticamente aceitável do mesmo e método de prevenção e/ou tratamento de um indivíduo que compreende a administração ao dito indivíduo uma quantidade terapeuticamente eficaz de um composto de fórmula
UY37837A (es) Nuevos compuestos heterocíclicos como inhibidores de cdk8/19
BR112017008312A2 (pt) novos compostos de piridopirimidinona para modular a atividade catalítica de histona lisina demetilases (kdms)
PH12019500328A1 (en) Aza-indazole compounds for use in tendon and/or ligament injuries
CO2021015614A2 (es) Terapias de combinación que comprenden inhibidores de apremilast y tyk2
ZA202109193B (en) A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator
CO2019002245A2 (es) Combinación de agonistas de fxr
MX2018004304A (es) DERIVADOS DE QUINOXALINA Y PIRIDOPRAZINA COMO INHIBIDORES DE PI3Kß.
SA519410865B1 (ar) مركب حلقي شبيه بكُومارين بوصفه مثبط mek واستخدامه
PH12019500327A1 (en) Indazole compounds for use in tendon and/or ligament injuries
BR112022008610A2 (pt) Composições tópicas compreendendo inibidores de irak4 para uso em tratamento de condições dermatológicas caracterizadas por inflamação
PE20220486A1 (es) Composiciones solidas que comprenden un derivado de egf(a) y una sal de acido n-(8-(2-hidroxibenzoil)amino)caprilico
MX2023001721A (es) Combinacion de regonafenib e inhibidores de pd-1/pd-l1(2) para el tratamiento contra el cancer.
ECSP22054240A (es) Compuesto y composici?n como inhibidor de quinasa del receptor pdgf
BR112022007616A2 (pt) Métodos e composições para tratar doença falciforme com um inibidor de ferroportina (vit-2763)
CL2021000627A1 (es) Composiciones farmacéuticas adecuadas para liberación articular y su uso en el tratamiento del dolor articular
CA3156340A1 (en) N-(1H-IMIDAZOL-2-YL)BENZAMIDE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING IT AS ACTIVE SUBSTANCE
CL2023002120A1 (es) Terapia combinada de un inhibidor de alk2 y un inhibidor de jak2
TW201611830A (en) Pharmaceutical formulation for reducing bladder spasms and method of use thereof